CommercialCoverageMedium impact
High-Dose Rate Temporary Prostate Brachytherapy
Blue Cross & Blue Shield of Mississippi·MS · Urology, Oncology, Radiology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for High-Dose Rate Temporary Prostate Brachytherapy, defining when the treatment is considered medically necessary versus investigational. The policy covers both monotherapy and combination with external-beam radiotherapy for localized prostate cancer and salvage therapy for recurrent cases.
Action Required
Immediately: Billing team should review all pending and future HDR prostate brachytherapy claims to ensure proper documentation of medical necessity criteria (prostate cancer risk levels, PSA levels, Gleason scores, clinical staging). Update prior authorization processes to verify patients meet coverage criteria for localized prostate cancer treatment or salvage therapy with biopsy-confirmed recurrence. Claims not meeting policy criteria will be denied as investigational.